◆ NeutralSPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
GlobeNewswire Inc.·
Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with a deadline of October 5, 2026 for investors to participate. The lawsuit alleges the company recklessly disregarded risks that could significantly impact insurance coverage guidance and commercialization of neffy.
Read Full Article at GlobeNewswire Inc. →